CTOs on the Move

Visa Solutions Healthcare

www.visasolutionshealthcare.com

 
Visa Solutions Healthcare is a healthcare division that connects partners with highly qualified international registered nurses and allied clinicians. They offer a Care for your Dream program to help nurses work in the U.S. and provide diagnostics so...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Canadian Federation of Biological Societies

Canadian Federation of Biological Societies is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SIRONA DENTAL SYSTEMS

Sirona Dental Systems, Inc. (Sirona) is a manufacturer of dental equipment. Sirona focuses on developing innovative systems and solutions for dentists globally.

Radicle Health

Radicle Health offers cannabis curriculum packages and modules for nurses, other healthcare professionals, and cannabis students at a range of price points.

Dong Bang

Dong Bang is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.